The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / CCL2 Cytokine Serves as Biomarker in Interstitial Lung Disease

CCL2 Cytokine Serves as Biomarker in Interstitial Lung Disease

December 18, 2017 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF

“We have been looking for predictive biomarkers and novel therapeutic targets,” he continues. “We postulated that inflammatory cytokines might predict the course of ILD. [And] with this research, we have demonstrated for the first time that CCL2 levels in the circulation [do predict] faster long-term decline.”

You Might Also Like
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • MUC5B Promoter Variant Associated with RA with Interstitial Lung Disease
Explore This Issue
December 2017

Previous experimental studies pointing to CCL2 as possibly correlated with the ILD severity used an animal model to reflect human disease, with murine sclerodermatous growth-vs.-host disease approximating the inflammation found in a subset of scleroderma, and with gene expression in skin transcript biopsy samples as an alternative to obtaining lung samples.2,3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The new findings provide further support for CCL2 as a research target, the authors conclude. Higher CCL2 levels in the circulation, after adjusting for other potential biomarkers, do predict faster ILD progression and poorer survival, supporting the notion CCL2 plays a role as a biomarker and may be a therapeutic target, Dr. Assassi says.

Predictive biomarkers can lead to more effective and individualized monitoring and treatment strategies, making it possible to more closely monitor SSc patients for progression of disease and potentially treat their disease more aggressively.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Larry Beresford is a freelance medical journalist in Oakland, Calif.

References

  1. Wu M, Baron M, Pedroza C, et al. CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: Data from two independent cohorts. Arthritis Rheumatol. 2017 Sep;69(9):1871–1878.
  2. Greenblatt MB, Sargent JL, Farina G, et al. Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol. 2012 Mar;180(3):1080–1094.
  3. Assassi S, Wu M, Tan FK, et al. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum. 2013 Nov;65(11):2917–2927.

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: ACR Journal Review, American College of Rheumatology, Biomarker, chemokine, Clinical, cytokine, early systemic sclerosis, forced vital capacity, ILD, Interstitial Lung Disease, lung function, outcome, patient care, Research, Rheumatic Disease, rheumatology, studyIssue: December 2017

You Might Also Like:
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • MUC5B Promoter Variant Associated with RA with Interstitial Lung Disease
  • What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)